Li Z, Becker J, Noe C R
Institut für Pharmazeutische Chemie, Frankfurt, Germany.
Eur J Biochem. 1998 Mar 15;252(3):391-9. doi: 10.1046/j.1432-1327.1998.2520391.x.
The yeast Saccharomyces cerevisiae was used for expressing the genes encoding the ionotropic N-methyl-D-aspartate (NMDA) receptor subunits from rats (NR1a, NR2A, NR2C) and mice (NR2B). Four plasmids were constructed by cloning the different NMDA receptor genes in the two multi-copy yeast-Escherichia coli shuttle vectors pMB01 (--> NR1a gene) and pMB02 (--> NR2A-2C genes). The protease-deficient S. cerevisiae strain cI3-ABYS-86 (leu-, ura-) was transformed or co-transformed with the resulting plasmids pMBNR1a (leu+) or pMBNR1a/pMBNR2A-C (ura+) respectively. Western blotting analysis with antibodies raised against amino acid sequences at the C-termini of the respective subunits revealed that the recombinant receptor proteins were differently expressed and only partially glycosylated in the cell membranes of the recombinant yeast strains. The expression and localization of the recombinant NMDA receptor proteins were also proved by immunofluorescence microscopy which indicated a distinct expression of the different NMDA receptor subunits in the plasma membrane of the transformed yeast cells. Pharmacological characterization of crude membrane preparations of the recombinant yeast cells showed saturable binding of the glycine antagonist [3H]MDL105,519 with Kd values of 56.9 +/- 6.19 nM (NR1a/NR2A), 26.72 +/- 2.13 nM (NR1a/NR2B), and 21.22 +/- 1.64 nM (NR1a/NR2C), and bound capacities of 17.94 +/- 1.24 pmol/mg membrane protein (NR1a/NR2A), 11.45 +/- 0.67 pmol/mg (NR1a/NR2B), and 16.15 +/- 0.86 (NR1a/NR2C) pmol/mg. The [3H]MDL105,519 binding was inhibited by the glycine antagonist 5,7-dichlorokynurenate, ethyl-2-carboxy-4,6-dichloro-3-indoleacetate, and itself, but not by glycine, D-serine or 1-amino-cyclopropanecarboxylic acid. Specific binding of [3H]glycine or the NMDA channel blocker [3H]dizolcipine were not observed.
酿酒酵母被用于表达编码来自大鼠(NR1a、NR2A、NR2C)和小鼠(NR2B)的离子型N-甲基-D-天冬氨酸(NMDA)受体亚基的基因。通过将不同的NMDA受体基因克隆到两个多拷贝酵母-大肠杆菌穿梭载体pMB01(用于NR1a基因)和pMB02(用于NR2A - 2C基因)中构建了四个质粒。分别用所得质粒pMBNR1a(亮氨酸+)或pMBNR1a/pMBNR2A - C(尿嘧啶+)转化或共转化蛋白酶缺陷型酿酒酵母菌株cI3 - ABYS - 86(亮氨酸缺陷型、尿嘧啶缺陷型)。用针对各亚基C末端氨基酸序列产生的抗体进行蛋白质印迹分析表明,重组受体蛋白在重组酵母菌株的细胞膜中表达不同且仅部分糖基化。免疫荧光显微镜也证实了重组NMDA受体蛋白的表达和定位,这表明不同的NMDA受体亚基在转化酵母细胞的质膜中有明显表达。重组酵母细胞粗膜制剂的药理学特性表明,甘氨酸拮抗剂[3H]MDL105,519具有饱和结合,其解离常数(Kd)值分别为56.9±6.19 nM(NR1a/NR2A)、26.72±2.13 nM(NR1a/NR2B)和21.22±1.64 nM(NR1a/NR2C),结合容量分别为17.94±1.24 pmol/mg膜蛋白(NR1a/NR2A)、11.45±0.67 pmol/mg(NR1a/NR2B)和16.15±0.86(NR1a/NR2C)pmol/mg。[3H]MDL105,519的结合受到甘氨酸拮抗剂5,7 - 二氯犬尿氨酸、乙基 - 2 - 羧基 - 4,6 - 二氯 - 3 - 吲哚乙酸及其自身的抑制,但不受甘氨酸、D - 丝氨酸或1 - 氨基环丙烷羧酸的抑制。未观察到[3H]甘氨酸或NMDA通道阻滞剂[3H]地佐环平的特异性结合。